# SignDo

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/signdo

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.signdosz.com
- Latest round: Series A (Mar 2, 2026)
- Investors on record: 2

## About

Established in 2021 and based in Suzhou, China,  SIGNDO Biotechnology (Suzhou) Co., Ltd, trading as SignDo, is a biotech company that focuses on developing tumor-targeted fluorescent contrast agents. In February 2026, SignDo raised a series A funding from Leader Venture Capital and OTHER.

The company's main business is the development and industrialization of tumor-targeted fluorescent contrast agents. The company has also built an RT-TFC™ R&D technology platform for the development of various Fluorescence- Drug Conjugate (FDC) for fluorescence-guided surgery.

The company's revenue is generated by providing doctors with tools required for tumor visualization. 

The Series A funding will primarily be used to accelerate product development, clinical trials, and industrialization, further solidifying the company's leading position in the field.

## Funding rounds

- Series A, Mar 2, 2026 — OTHER, Leader Venture Capital

## Investors

- OTHER — Series A
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series A